1 trials tracked · 1 active · last refreshed 2026-08-10
Bemdaneprocel (BlueRock Therapeutics, a Bayer subsidiary) is a stem-cell-derived dopamine neuron replacement therapy — rather than a drug that modulates existing biology, it's a one-time neurosurgical implant of lab-grown dopaminergic neurons intended to physically replace the cells Parkinson's destroys. Its only tracked trial (Phase III) follows an earlier Phase I trial that reported the implanted cells survived and produced dopamine in patients' brains — an early but genuinely novel proof of concept for a disease with no regenerative treatment today.
Being surgical rather than a pill or infusion, it's a fundamentally different treatment category from every other drug tracked here — success would open an entirely new class of Parkinson's therapy, but it also carries the risks and practical limits of any implanted-cell approach.
Click a row for what it's testing, where, and how many participants.
| NCT ID | Title | Phase | Status | Started | |
|---|---|---|---|---|---|
| ▸ | NCT06944522 | A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease | Phase III | Recruiting | 2025-06-17 |
Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD). Enrollment 102 (estimated) Sites 43 across 3 countries Countries Australia, Canada, United States Sponsor BlueRock Therapeutics Primary outcome: Change from baseline in PD diary measure of ON-time without troublesome dyskinesia, adjusted for a 16-hour waking day | |||||
This page is regenerated from ClinicalTrials.gov data and summarized once per refresh — nothing here is generated live when you visit. For informational purposes only; not medical advice.